Genetic Analysis AS (FRA:8V8) Change In Payables And Accrued Expense : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS Change In Payables And Accrued Expense?

Genetic Analysis AS's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was €0.00 Mil. It means Genetic Analysis AS's Accounts Payable & Accrued Expense stayed the same from Sep. 2023 to Dec. 2023 .

Genetic Analysis AS's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Genetic Analysis AS's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Genetic Analysis AS Change In Payables And Accrued Expense Historical Data

The historical data trend for Genetic Analysis AS's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Analysis AS Change In Payables And Accrued Expense Chart

Genetic Analysis AS Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Genetic Analysis AS Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial										-	-	-	-	-

Genetic Analysis AS Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Genetic Analysis AS Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Genetic Analysis AS's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Analysis AS (FRA:8V8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (FRA:8V8) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

GEAN:Sweden

Address

Kabelgata 8, Oslo, NOR, 0580

Website

https://www.genetic-analysis.com

Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS (FRA:8V8) Headlines

No Headlines